Posted by Michael Wonder on 03 Apr 2024
RemeGen's telitacicept (RC18) granted fast track designation by US FDA for treatment of primary Sjögren's syndrome
2 April 2024 - RemeGen has obtained fast track designation by the US FDA recently for its innovative BLyS/APRIL dual-target fusion protein drug, telitacicept (RC18), independently developed by RemeGen for the treatment of patients with primary Sjögren's syndrome.
Independently developed by RemeGen, Telitacicept is an innovative BLyS/APRIL dual-target fusion protein drug that simultaneously inhibits the overexpression of two cytokines, B-cell lymphocyte stimulator and a proliferation-inducing ligand.
